James O. Jones

University of Cambridge — United Kingdom

Medicine · Health Sciences

11h-index3.9kcitations48works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(21), Renal and related cancers(11), Cancer Immunotherapy and Biomarkers(10), Cancer Genomics and Diagnostics(7), Immunotherapy and Immune Responses(5)

Publications48 total

Deconvolving metabolic intratumoral heterogeneity in clear cell renal carcinoma with hyperpolarized 13C-pyruvate MRI
2026Open Access
Evaluating Foundation Models with Pathological Concept Learning for Kidney Cancer
Lecture notes in computer science·2026
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI
Abdominal Radiology·2025Open Access
Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study
European Urology Oncology·2025· 1 citedOpen Access
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
The Lancet Oncology·2025· 4 citedOpen Access
10Investigating the mechanisms of neoadjuvant olaparib and cediranib in renal cancer: results of arms 1 to 3 of the WIndow of opportunity in REnal cancer (WIRE) clinical trial
The Oncologist·2025Open Access
Evaluating Foundation Models with Pathological Concept Learning for Kidney Cancer
2025Open Access
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarised [1-13C]pyruvate-MRI
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2025
Integrating Pathology and CT Imaging for Personalized Recurrence Risk Prediction in Renal Cancer
arXiv (Cornell University)·2025Open Access
What is required to deliver practice-changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study
Annals of Oncology·2025· 3 cited
A network medicine framework for multi-modal data integration in therapeutic target discovery
2025Open Access
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
MANIFEST: Multiomic Platform for Cancer Immunotherapy
Cancer Discovery·2025· 3 citedOpen Access
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
Angiogenic and immune predictors of neoadjuvant axitinib response in renal cell carcinoma with venous tumour thrombus
Nature Communications·2025· 2 citedOpen Access
Abstract CT175: Neoadjuvant olaparib and cediranib in renal cancer: Outcomes of the WIndow-of-opportunity in REnal cancer (WIRE) Trial
Cancer Research·2025
Abstract 1103: Multi-modal machine learning identifies predictive biomarkers of response to neoadjuvant axitinib in renal cell carcinoma with venous tumor thrombus
Cancer Research·2025
Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus
2024· 1 citedOpen Access
The current state of digital pathology, molecular diagnostics and biobanking in renal cancer: Kidney Cancer Association Consensus Statement
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Grant D. Stewart(25), Sarah J. Welsh(19), Anne Y. Warren(19), Thomas J. Mitchell(16), Ferdia A. Gallagher(13), Brent O’Carrigan(12), Stephan Ursprung(10), Alexander Laird(10), Will Ince(10), Andrew N. Priest(9), Iosif Mendichovszky(8), James N. Armitage(8), Ines Horvat‐Menih(8), Mireia Crispin‐Ortuzar(8), Lauren Wallis(7), Antony C. P. Riddick(6), James P. Blackmur(6), Zayd Tippu(6), Mary A. McLean(6), Farhana Easita(6)